Skip to main content
. 2016 Sep 20;36(5):2489–2500. doi: 10.3892/or.2016.5112

Figure 2.

Figure 2

Clinical relevance of SHMT2 in breast cancer. Protein expression levels of SHMT2 and other biomarkers were determined using immunohistochemistry (IHC) staining. (A) Representative IHC images stained with SHMT2 (magnification, ×200). (B) SHMT2 protein expression levels associated with pathological tumor and lymph node stage (pT and pN stages), poor differentiation and MKI-67 in ZJU set. Here, pT is pathological tumor stage; and the number represent tumor stage. pN is pathological lymph node stage; the number indicates how many lymph nodes involved. pN>3 is >3 lymph nodes were involved. Mod, moderate differentiation; Neg, negative; Pos, positive. (C) ANOVA analysis result for SHMT2 mRNA expression levels and tumor size, pN and TNM stages, Elson grade, and intrinsic molecular subtypes of breast cancer. TNBC, basal-like breast cancer; HER2, Her2-positive, LA, luminal A; LB, luminal B; NL, normal breast-like. The p-values represent overall ANOVA analysis results.